Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient
Psoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. The lesions are typically characterized by sharply demarcated, erythematous plaques covered with silvery scales. Treatment options include topical agents, phototherapy, systemic the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573495/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329238451159040 |
|---|---|
| author | Jianhao Ke Meiliang Guo Xuan Zhao Na Liu Qinqin Meng Hui Deng |
| author_facet | Jianhao Ke Meiliang Guo Xuan Zhao Na Liu Qinqin Meng Hui Deng |
| author_sort | Jianhao Ke |
| collection | DOAJ |
| description | Psoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. The lesions are typically characterized by sharply demarcated, erythematous plaques covered with silvery scales. Treatment options include topical agents, phototherapy, systemic therapies, and biologic agents. Traditional systemic treatments are generally contraindicated in patients with cancer due to their immunosuppressive effects. Although biologics are widely used in the management of psoriasis, their safety in patients with malignancy remains insufficiently evaluated, as individuals with cancer are typically excluded from clinical trials due to concerns about cancer progression. We report the case of a 61-year-old man whose psoriasis markedly worsened following treatment with sintilimab for pulmonary metastases secondary to colon cancer. The patient was successfully treated with guselkumab, an interleukin (IL)-23 inhibitor, resulting in significant improvement in psoriasis symptoms, while the pulmonary condition remained stable during follow-up after completion of standard cancer therapy. This case highlights the potential utility of IL-23 inhibitors as safe and effective treatment options for patients with concomitant psoriasis and malignancy. |
| format | Article |
| id | doaj-art-7fbfba227bec48ad8de7c50187d23ee4 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7fbfba227bec48ad8de7c50187d23ee42025-08-20T03:47:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15734951573495Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patientJianhao KeMeiliang GuoXuan ZhaoNa LiuQinqin MengHui DengPsoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. The lesions are typically characterized by sharply demarcated, erythematous plaques covered with silvery scales. Treatment options include topical agents, phototherapy, systemic therapies, and biologic agents. Traditional systemic treatments are generally contraindicated in patients with cancer due to their immunosuppressive effects. Although biologics are widely used in the management of psoriasis, their safety in patients with malignancy remains insufficiently evaluated, as individuals with cancer are typically excluded from clinical trials due to concerns about cancer progression. We report the case of a 61-year-old man whose psoriasis markedly worsened following treatment with sintilimab for pulmonary metastases secondary to colon cancer. The patient was successfully treated with guselkumab, an interleukin (IL)-23 inhibitor, resulting in significant improvement in psoriasis symptoms, while the pulmonary condition remained stable during follow-up after completion of standard cancer therapy. This case highlights the potential utility of IL-23 inhibitors as safe and effective treatment options for patients with concomitant psoriasis and malignancy.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573495/fullimmune checkpoint therapycutaneous adverse effectspsoriasisbiologicscancer |
| spellingShingle | Jianhao Ke Meiliang Guo Xuan Zhao Na Liu Qinqin Meng Hui Deng Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient Frontiers in Immunology immune checkpoint therapy cutaneous adverse effects psoriasis biologics cancer |
| title | Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient |
| title_full | Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient |
| title_fullStr | Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient |
| title_full_unstemmed | Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient |
| title_short | Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient |
| title_sort | case report guselkumab treatment for sintilimab exacerbated psoriasis in a cancer patient |
| topic | immune checkpoint therapy cutaneous adverse effects psoriasis biologics cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573495/full |
| work_keys_str_mv | AT jianhaoke casereportguselkumabtreatmentforsintilimabexacerbatedpsoriasisinacancerpatient AT meiliangguo casereportguselkumabtreatmentforsintilimabexacerbatedpsoriasisinacancerpatient AT xuanzhao casereportguselkumabtreatmentforsintilimabexacerbatedpsoriasisinacancerpatient AT naliu casereportguselkumabtreatmentforsintilimabexacerbatedpsoriasisinacancerpatient AT qinqinmeng casereportguselkumabtreatmentforsintilimabexacerbatedpsoriasisinacancerpatient AT huideng casereportguselkumabtreatmentforsintilimabexacerbatedpsoriasisinacancerpatient |